Eugene Toy, MD
Gynecologic Oncology · El Paso, TXNPI 1962412668
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $112,435 of the $138,314 with a category attached, or 81.3%. AstraZeneca accounts for 99.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $99,440 and has fallen 98.6% since, to $1,433 in 2025. Among gynecologic oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $875.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$137K
- Biom'up SA$397
- GSK$274
- Genmab U.S., Inc.$219
- Biom'up France SAS$117
- Seagen Inc.$99
- plus $125 from 4 others
What the payments were for
- Consulting fees$3,3302%
- Speaking & faculty fees$112,43581%
- Travel & lodging$18,53713%
- Food & beverage$3,9133%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 125 | $137,085 |
| Biom'up SA | 8 | $397 |
| GSK | 7 | $274 |
| Genmab U.S., Inc. | 5 | $219 |
| Biom'up France SAS | 7 | $117 |
| Seagen Inc. | 1 | $99 |
| Masimo Corporation | 1 | $42 |
| Merck | 2 | $40 |
| Foundation Medicine, Inc. | 1 | $27 |
| Clovis Oncology, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$138,314 in reported general payments places this provider in the 90th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 30 | $246 |
| Dexamethasone | 39 | $180 |
| Oxycodone Hcl | 13 | $170 |
| Gabapentin | 11 | $139 |
| Ondansetron Hcl | 17 | $39 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in El Paso
- Jose SaldivarEl Paso$64K
- Julia ChapmanEl Paso$15K
- Wafic MassryEl Paso$4K
- Robert ColemanHouston$864K
- Reagan StreetFort Worth$280K
- Joseph de la GarzaSan Antonio$234K
- Maurie MarkmanHouston$204K
- Dustin MandersDallas$171K
- Tiffany RedfernFort Worth$165K
- Antonio Santillan-GomezSan Antonio$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.